Description of Enfuvirtide Acetate:Cas No. 159519-65-0
Molecular Formula C204H301N51O64
Molecular Weight 4492
Specifications of Enfuvirtide Acetate:
Purity (HPLC) 98.0%min.
Appearance: White to off-white amorphous solid
Single Impurity (HPLC): 0.5%max
Amino Acid Composition: ±10% of theoretical
Peptide Content (N%): ≥80.0%
Water Content (Karl Fischer) : ≤8.0%
TrifluoroAcetate Content(HPIC): ≤12.0%
MS (ESI): Consistent
Mass Balance: 95.0~105.0%
Enfuvirtide (INN) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
Enfuvirtide therapy costs an estimated US$25,000 per year in the United States. Its cost and inconvenient dosing regimen are factors behind its use as a reserve, for "salvage" therapy in patients with multi-drug resistant HIV.
No comments:
Post a Comment